{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:25:23Z","timestamp":1760217923266},"reference-count":64,"publisher":"Informa UK Limited","issue":"31","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2019,11,30]]},"DOI":"10.2217\/fon-2019-0193","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T13:21:35Z","timestamp":1568985695000},"page":"3565-3578","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["The Role of Obinutuzumab in the Management of Follicular Lymphoma"],"prefix":"10.1080","volume":"15","author":[{"given":"Jenny","family":"O\u2019Nions","sequence":"first","affiliation":[{"name":"NIHR\/UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Townsend","sequence":"additional","affiliation":[{"name":"NIHR\/UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK"},{"name":"Department of Haematology, Cancer Institute, University College London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,9,20]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612-x"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491514"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.503"},{"key":"e_1_3_3_9_1","volume-title":"60 Years of Survival Outcomes at the University of Texas MD Anderson Cancer Center.","year":"2013","unstructured":"S N. 60 Years of Survival Outcomes at the University of Texas MD Anderson Cancer Center.Springer, NY, USA (2013)."},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S34273"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.3402"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08969.x"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00262JCO1800262"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9718"},{"key":"e_1_3_3_20_1","first-page":"486","article-title":"Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years","volume":"130","author":"Salles GA","year":"2017","unstructured":"Salles GA , SeymourJF, FeugierPet al. Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years. Blood130, 486 (2017).","journal-title":"Blood"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-263533"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.6.3176"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M708459200"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.5.3351"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-149161"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.001628"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2031"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22771"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145633"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"e_1_3_3_32_1","first-page":"3022","article-title":"Obinutuzumab activates CD64 more potently than other anti-CD20 antibodies in chronic lymphocytic leukaemia (CLL)","volume":"130","author":"Elias S","year":"2017","unstructured":"Elias S , KahlonS, KotzurR, KaynanN, MandelboimO. Obinutuzumab activates CD64 more potently than other anti-CD20 antibodies in chronic lymphocytic leukaemia (CLL). Blood130, 3022 (2017).","journal-title":"Blood"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400288"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-1182"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202588"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15232"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-395541"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.93"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0451-1"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2015.1087844"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2139"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30097-3"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.3656"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.6.6"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8960"},{"key":"e_1_3_3_47_1","first-page":"1597","article-title":"Obinutuzumab-based immunochemotherapy prolongs progression-free survival and time to next anti-lymphoma treatment in patients with previously untreated follicular lymphoma: four-year results from the Phase III GALLIUM study","volume":"132","author":"Townsend W","year":"2018","unstructured":"Townsend W , BuskeC, CartronGet al. Obinutuzumab-based immunochemotherapy prolongs progression-free survival and time to next anti-lymphoma treatment in patients with previously untreated follicular lymphoma: four-year results from the Phase III GALLIUM study. ASH Abstract132, 1597 (2018).","journal-title":"ASH Abstract"},{"key":"e_1_3_3_48_1","first-page":"1490","article-title":"Early disease progression predicts poorer survival in patients with follicular lymphoma (FL) in the GALLIUM study","volume":"130","author":"Launonen A","year":"2017","unstructured":"Launonen A , HiddemannW, DuenzingerU, Fingerle-RowsonG, NielsenT, MarcusR. Early disease progression predicts poorer survival in patients with follicular lymphoma (FL) in the GALLIUM study. Blood130, 1490 (2017).","journal-title":"Blood"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu208"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-380949"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2165"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011430506"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.10.7435"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7504"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1706154"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.613.613"},{"key":"e_1_3_3_57_1","first-page":"396","volume-title":"ASH Annual Meeting Abstract","author":"Pott C","year":"2018","unstructured":"Pott C , HosterE, KehdenBet al. Minimal residual disease response at end of induction and during maintenance correlates with updated outcome in the Phase III GALLIUM study of obinutuzumab- or rituximab-based immunochemotherapy in previously untreated follicular lymphoma patients. ASH Annual Meeting Abstract. CA, USA, 396 (2018)."},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30618-1"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1159\/000381524"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS7578"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-853499"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.5104.5104"},{"key":"e_1_3_3_63_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e19052","article-title":"Preliminary safety, pharmacokinetics, and pharmacodynamics of duvelisib plus rituximab or obinutuzumab in patients with previously untreated CD20+ follicular lymphoma","volume":"34","author":"Casulo C","year":"2016","unstructured":"Casulo C , JacobsenED, EygenKVet al. Preliminary safety, pharmacokinetics, and pharmacodynamics of duvelisib plus rituximab or obinutuzumab in patients with previously untreated CD20+ follicular lymphoma. J. Clin. Oncol.34(Suppl.), (2016).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.2742.2742"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.4981.4981"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175208"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2019-0193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:14Z","timestamp":1719125174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2019-0193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,20]]},"references-count":64,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2019,11,30]]}},"alternative-id":["10.2217\/fon-2019-0193"],"URL":"https:\/\/doi.org\/10.2217\/fon-2019-0193","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}